<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01778283</url>
  </required_header>
  <id_info>
    <org_study_id>297/55</org_study_id>
    <nct_id>NCT01778283</nct_id>
  </id_info>
  <brief_title>Comparison of Cardiac Index and Cardiac Output Effect During Maintenance Hemodialysis Between Acetate-Free and Acetate-Based Online Hemodiafiltration</brief_title>
  <official_title>Comparison of Cardiac Index and Cardiac Output Effect During Maintenance Hemodialysis Between Acetate-Free and Acetate-Based Online Hemodiafiltration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to detemine whether effect of Acetate-free solution on cardiac
      index and cardiac output measured by saline dilution techniques compares with Acetate-based
      solution in online-hemodiafiltration
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiac index</measure>
    <time_frame>6 months</time_frame>
    <description>cardiac index and cardiac output was measured by ultrasound dilution technique</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>6 months</time_frame>
    <description>cardiac index and cardiac output was measured by ultrasound dilution technique</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peripheral vascular resistance</measure>
    <time_frame>6 moths</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>dizziness, palpitation, nausea, cramp, numbness</description>
  </secondary_outcome>
  <other_outcome>
    <measure>cardiac marker, serum electrolyte, inflammatory marker</measure>
    <time_frame>January 2013</time_frame>
    <description>BUN, creatinine, serum sodium, serum potassium, serum bicarbonate, serum calcium, ionized calcium, serum magnesium, serum osmol, troponin T, NT-proBNP, CKMB, hs-CRP</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Acetate-free solution first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetate-free solution first : hemodialysis 4 hours with Acetate-free solution (Acetate 0 mEq/L Citrate 2 mEq/L) at the first session after enrollment, and then switch to Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the next 4-hr hemodialysis session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetate-based solution first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetate-based solution first : hemodialysis 4 hours with Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the first session after enrollment, and then switch to Acetate-free solution (Acetate 2 mEq/L Citrate 2 mEq/L) at the next 4-hr hemodialysis session</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Acetate-free dialysis solution</intervention_name>
    <description>the hemodialysis solution that does not contain acetate as buffer</description>
    <arm_group_label>Acetate-free solution first</arm_group_label>
    <arm_group_label>Acetate-based solution first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  End-stage renal disease patients with age over 20 years and stable clinical status

          -  Dialytic age &gt; 6 months

          -  Maintenance hemodialysis with online-hemodiafiltration mode at King Chulalongkorn
             Memorial Hospital

          -  Use arteriovenous fistula or arteriovenous graft as vascular access for hemodialysis

          -  No vascular access recirculation

          -  No liver impairment

          -  No severe, intractable metabolic acidosis or alkalosis (HCO3 &lt;15, &gt;30)

          -  No pre-existing severe, intractable hypocalcemia (Ca &lt; 7.5) or clinical of
             hypocalcemia

        Exclusion Criteria:

          -  On hemodialysis via tunnel catheter

          -  Vascular access recirculation

          -  Liver dysfunction

          -  Severe, intractable metabolic acidosis or alkalosis (HCO3 &lt;15, &gt;30)

          -  Pre-existing severe, intractable hypocalcemia (Ca &lt; 7.5) or clinical of hypocalcemia

          -  Acute or recent myocardial ischemia or congestive heart failure (within 1 months)

          -  Threatening arrhythmia (VT, VF, sustained SVT, AF with rapid ventricular response)

          -  Patients affected by acute or chronic infections, malignant tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>January 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <last_update_submitted>February 12, 2013</last_update_submitted>
  <last_update_submitted_qc>February 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Khajohn Tiranathanagul</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

